Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.

Emily L HeilKimberly C ClaeysEllen G KlineTara M RogersKevin M SquiresAlina IovlevaYohei DoiMary BanoubMandee M NovalPaul M LuethyRyan K Shields

Published in: The Journal of antimicrobial chemotherapy (2023)

Use of three-drug regimens for severe CRAB infections among COVID-19 resulted in high rates of clinical response and low mortality relative to previous studies. The emergence of further antibiotic resistance was not detected phenotypically or through WGS analysis. Additional studies are needed to elucidate preferred antibiotic combinations linked to the molecular characteristics of infecting strains.

Keyphrases

sars cov
coronavirus disease
case control
escherichia coli
drug induced
adverse drug
early onset
risk factors
emergency department
single molecule
respiratory syndrome coronavirus
type diabetes
cardiovascular disease